Expe perience ces s in Delivery of e-Infrastr structu ctures s for Po Post- st-Genomic c Biomedi dica cal Rese search ch
Professor Richard O. Sinnott Director, eResearch 24th March 2011
Expe perience ces s in Delivery of e-Infrastr structu ctures s - - PowerPoint PPT Presentation
Expe perience ces s in Delivery of e-Infrastr structu ctures s for Po Post- st-Genomic c Biomedi dica cal Rese search ch Professor Richard O. Sinnott Director, eResearch 24 th March 2011 rsinnott@unimelb.edu.au e- Expensive!?
Professor Richard O. Sinnott Director, eResearch 24th March 2011
2
3
Services
the Cellular Level
ShinTau
Electronics (nanoCMOS)
(DAMES)
(SHIP)
(NeISS)
Researchers (ENROLLER)
Tumors Cancer Research Platform
(DiPAR)
Bardet Biedl
4
– Someti times s pa painful bu but t always s ach chieved! d!
– Some have bl blazed d a tr trail and d are now use sed d in ange ger
5
Nucleotide sequences Nucleotide structures Gene expressions Protein Structures Protein functions Protein-protein interaction (pathways) Cell Cell signalling Tissues Organs Physiology Organisms Populations
6
Synteny Service
Information Integrator OGSA-DAI
Magna Vista Service
VO Authorisation
Glasgow Edinburgh Leicester Oxford London Netherlands
Public ally Curated Data Private data Private data Private data Private data Private data Private data
CFG Virtual Organisation
Ensembl MGI HUGO OMIM SWISS - PROT
…
DATA HUB
RGD
7
8
9
10
11
competitors
12
– Inter-organisational collaborations – Data and data management – Security – High performance computing – Visualisation
» approximately in that order!
– Simply paying lip service here simply won’t cut it in the real world! » Disclosure Scotland
13
14
15
– Committees / bodies – Structures and processes
– Opt-in – Opt-out
– Local only – National only – EuroDSD collaborators only – All international DSD researchers
Designed with worst case scenarios in mind!
16
ethics across all countries/sites)
17
18
Czech Rep, Estonia, Jordan, Kuwait, Morocco, Poland, Portugal, Spain, Sudan, Turkey, UK, USA, … (+
28.30% ¡ 23.85% ¡ 11.76% ¡ 8.27% ¡ 6.68% ¡ 6.52% ¡ 4.61% ¡ 4.45% ¡ 3.34% ¡ 2.23% ¡ Ro/erdam ¡ Cambridge ¡ Luebeck ¡ Pisa ¡ Ghent ¡ Lyon ¡ Glasgow ¡ Stockholm ¡ Birmingham ¡ Kiel ¡
20 40 60 80 100 120 140 17/12/08 16/01/09 09/02/09 02/03/09 17/03/09 31/03/09 27/04/09 13/05/09 27/05/09 21/07/09 16/08/09 22/09/09 17/10/09 05/11/09 17/11/09 Cambridge Glasgow Kiel Luebeck Rotterdam Birmingham Stockholm Ghent Pisa Lyon19
20
21
22
– Two major drug trials » 2500 patients in each; Mitotane/Sunitinib for ACC/Pheo » Other trials already identified and will be supported
23
24
Plasma Free Metanephrines PFM Urine Free Metanephrines UFM Urine Deconjugated Metanephrines UDM Plasma Catecholamines PCA Urine Catecholamines UCA Urine Overnight Sample UON Plasma Chromogranin A CGA Blood DNA Sample (leukocytes) DNA Plasma Sample for Banking PBK Urine Sample for Banking UBK Tumor Tissue Sample TUM
– 1PF PFRPA1-003
– 1PF PFRPA1-003TUM007
Plus s sta standa dardi disa sati tion of gu guide delines s
storage ge, sh shippi pping, g, handl dling g etc) tc)
25
– Centralised, federated data models – Dependent/independent database – Push vs pull querying models
– Carrot and stick!!!
26
26 ¡